Vortosiran in Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 150 participants.

Also called NCT07870889

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07870889
  • EudraCT 2026-525417-31
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Norway, Poland, Sweden (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07870889. Randomized; quadruple masking; primary purpose treatment. Start 2026-10-01 (anticipated); primary completion 2028-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vortosiran in Atrial Fibrillation
Condition
Non-valvular Atrial Fibrillation (AF)
Intervention (Drug)
Vortosiran
Intervention (Drug)
Vortosiran
Intervention (Drug)
Apixaban
Lead sponsor
Ribocure Pharmaceuticals AB (class: industry)
Collaborator
Link Medical Research AB (class: industry)

Record details

Record id
cardio:ct-nct07870889
Content hash
87f79ede2a2b715ecd5050dee6fa4bf0f7d7bb2db77755b76e072d21b853cad2